Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,390
  • Shares Outstanding, K 1,775
  • Annual Sales, $ 1,530 K
  • Annual Income, $ -93,440 K
  • EBIT $ -35 M
  • EBITDA $ -37 M
  • 60-Month Beta -0.02
  • Price/Sales 4.17
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.24
  • Number of Estimates 1
  • High Estimate -1.24
  • Low Estimate -1.24
  • Prior Year -8.00
  • Growth Rate Est. (year over year) +84.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.84 +26.76%
on 11/25/25
4.59 -21.57%
on 12/05/25
+0.13 (+3.75%)
since 11/19/25
3-Month
2.84 +26.76%
on 11/25/25
8.75 -58.85%
on 10/06/25
-2.75 (-43.31%)
since 09/19/25
52-Week
2.84 +26.76%
on 11/25/25
37.50 -90.40%
on 06/02/25
-4.90 (-57.65%)
since 12/19/24

Most Recent Stories

More News
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

–  Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12,...

LYRA : 3.60 (-3.23%)
William Blair Keeps Their Hold Rating on Lyra Therapeutics (LYRA)

In a report released today, Lachlan Hanbury Brown from William Blair maintained a Hold rating on Lyra Therapeutics. The company’s shares closed yesterday at $7.92.Elevate Your Investing Strategy: Take...

LYRA : 3.60 (-3.23%)
William Blair Reaffirms Their Hold Rating on Lyra Therapeutics (LYRA)

William Blair analyst Lachlan Hanbury Brown maintained a Hold rating on Lyra Therapeutics today. The company’s shares opened today at $7.47.Elevate Your Investing Strategy: Take advantage of TipRanks...

LYRA : 3.60 (-3.23%)
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission  Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct....

LYRA : 3.60 (-3.23%)
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210...

LYRA : 3.60 (-3.23%)
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

LYRA : 3.60 (-3.23%)
Wall Street rises again as US stocks pull closer to their records

U.S. stocks drifted higher and pulled closer to their record as the wait continues for more updates on President Donald Trump’s tariffs and how much they’re affecting the economy

META : 658.77 (-0.85%)
NVDA : 180.99 (+3.93%)
GOOGL : 307.16 (+1.55%)
DG : 137.28 (+0.44%)
AVGO : 340.36 (+3.18%)
CEG : 355.40 (-1.56%)
GM : 82.35 (+1.45%)
F : 13.47 (+1.13%)
$SPX : 6,834.50 (+0.88%)
$IUXX : 25,346.18 (+1.31%)
$DOWI : 48,134.89 (+0.38%)
LYRA : 3.60 (-3.23%)
Wall Street drifts higher as oil prices jump and US manufacturing slumps

U.S. stock indexes drifted closer to records, coming off their stellar May

NVDA : 180.99 (+3.93%)
META : 658.77 (-0.85%)
ULTA : 597.88 (+0.65%)
DG : 137.28 (+0.44%)
CVX : 147.75 (+0.04%)
COP : 91.94 (-0.31%)
$SPX : 6,834.50 (+0.88%)
DLTR : 127.84 (+0.74%)
GM : 82.35 (+1.45%)
F : 13.47 (+1.13%)
$IUXX : 25,346.18 (+1.31%)
UNH : 327.42 (-0.22%)
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

LYRA : 3.60 (-3.23%)
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

LYRA : 3.60 (-3.23%)

Business Summary

Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and...

See More

Key Turning Points

3rd Resistance Point 4.39
2nd Resistance Point 4.21
1st Resistance Point 3.91
Last Price 3.60
1st Support Level 3.43
2nd Support Level 3.25
3rd Support Level 2.95

See More

52-Week High 37.50
Fibonacci 61.8% 24.26
Fibonacci 50% 20.17
Fibonacci 38.2% 16.08
Last Price 3.60
52-Week Low 2.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar